ArticleRedox biology2026
Nitric oxide generates a coordinated histone modification signature consistent with chromatin compaction, linked to methyl-modifying enzyme dysregulation and tumor-permissive gene silencing.
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Our laboratory has established that the free radical signaling molecule nitric oxide (NO) is an endogenous regulator of epigenetic methylation through direct inhibition of the Fe(II)/2-oxoglutarate-dependent dioxygenase (2-ODD) family, including histone demethylases (KDMs)[1, 2], mRNA demethylases (FTO, ALKBH5) [3], and DNA demethylases (TETs, ALKBH2) [4]. We previously showed that NO alters 38 histone post-translational modifications (PTMs) and genome-wide transcription in breast cancer cells [3]. Here, we comprehensively quantify 76 histone modifications, including 30 combinatorial marks on adjacent residues not resolved in the original analysis, and systematically profile methyl-modifying enzyme expression. We identify four coordinated histone PTM axes converging on a chromatin compaction signature: (i) H3K9 methylation accumulation with selective K9me1K14ac remodeling, (ii) H4K20me1→me2/me3 conversion, (iii) a novel H3K27-K36 combinatorial landscape shift, and (iv) preferential depletion of hyperacetylated H4 species. A composite Chromatin Compaction Score integrating all 76 PTMs with literature-based valence assignments confirms progressive compaction, validated independently by PCA. ChIP-seq reanalysis reveals that H3K9me2 accumulates predominantly at intergenic regions while K9ac undergoes activity-dependent redistribution governed by baseline chromatin state, with near-perfect reciprocal H3K9me2 gain at silent loci. Systematic enzyme profiling shows coordinated upregulation of 13/18 detected KDMs alongside methyltransferase downregulation, a compensatory response that fails to overcome direct enzymatic inhibition by NO. This compaction signature is associated with tumor-permissive gene silencing: DNA repair genes are downregulated, chromatin remodeling complexes suppressed, and IDH1 downregulation creates a feed-forward loop compounding 2-ODD inhibition. These findings establish NO-mediated KMD inhibition as a driver of coordinated chromatin compaction linked to pro-tumorigenic gene silencing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.